ClinicalTrials.gg
RecruitingNCT05287321HUGSUpdated Nov 2, 2026

The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia

A Phase 3 interventional study of Hydroxychloroquine in Preeclampsia, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to female participants aged 19 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Samsung Medical Center · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2022; still recruiting 4 years 5 months later.
Updated Nov 2, 2026Primary completion movedSponsor changedGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
19 Years to 50 Years
Sex
Female
01

Study summary

This study is prospective, single arm group ,open label, and multicenter trial (with two parallel-group [Hydroxychloroquine 200mg with Aspirin 100mg or Aspirin 100mg])

Read the detailed description

This study is prospective, open label, and multicenter trial [Hydroxychloroquine 200mg with Aspirin 100mg]

The study population consists of the singleton pregnancy at high risk for preeclampsia who had adverse pregnancy outcome (preeclampsia or fetal growth restriction or intrauterine fetal death) in previous pregnancy.

After randomisation, participants are assigned to receive hydroxychloroquine 200mg with aspirin 100mg per day or aspirin 100mg per day. Treatment is initiated between 12 and 22 weeks' gestation and stopped at 36 weeks' gestation.

The medication adherence to dosing should be maintained at more than 80%.

02

Conditions studied

  • Preeclampsia

Browse trials for

03

In context

Pre-Eclampsia

916 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

This study's planned enrollment of 58 is below the median of 110 across 480 interventional studies indexed under Pre-Eclampsia.

Browse Pre-Eclampsia studies →

Lead sponsor

Samsung Medical Center is the lead sponsor of 1,011 studies on the registry; 152 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The singleton pregnant women aged from 19 to 50 years
  2. Includes at least one factors of the below

    ① History of preeclampsia

    ② History of fetal growth restriction

    ③ History of intrauterine fetal death

  3. Women who have agreed to enroll in the study and given their

Exclusion criteria

Exclusion Criteria:

  1. Indication to a treatment according to the severe cardiovascular, immune, respiratory, gastrointestinal/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, psychiatric, infectious disease and (However, the participation of the trial is allowed by the investigator based on medically necessary.)
  2. Previous inclusion in other intervention study within 3 months of screening (except for non-interventional observational studies)
  3. Major malformation of the fetus is diagnosed at 11-13 weeks of gestation
  4. Elevated blood concentrations of creatinine more than double the normal value
  5. Elevated blood concentrations of liver transaminases ((GOT) or ALT(GPT)) more than three times the normal value
  6. Conditions related with aspirin treatment

    • Previous exposure within 28 days of screening
    • Previous NSAID exposure within 28 days of screening
    • Bleeding disorder (von Willebrand's disease, peptic ulceration)
    • to aspirin
  7. Conditions related with hydroxychloroquine treatment

    • Previous exposure within 28 days of screening
    • Hypersensitivity to hydroxychloroquine and 4-aminoquinoline compounds
    • Maculopathy
    • Medications that has potential for visual disturbance
    • Women who have potential for changes in the retina or visual impairment by 4-aminoquinoline compounds
    • Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
    • Prolonged on (congenital or acquired) or The risk factors of QT prolongation (heart failure, arrhythmia, myocardial ischemia)
    • Low level of potassium in the blood
    • Low level of magnesium in the blood
  8. Not suitable for participant based on medical evidence by investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Aspirin 100mg + Hydroxychloroquine 200mg

    Aspirin 100mg 1T daily PO + Hydroxychloroquine 200mg 1T daily PO

    Drug: Hydroxychloroquine

Interventions

06

What researchers measure

Primary outcomes

  1. Composite morbidity

    Preeclampsia, Fetal growth restriction, Intrauterine fetal death, preterm delviery (\<37weeks)

    Time frame: gestational period

Secondary outcomes

  1. Severe preeclampsia

    with severe features: severe features are uncontrolled BP (systolic BP \> 160mm Hg or diastolic BP \> 110mm Hg on two occasions at least 4hours apart), persistent epigastric pain, new onset headaches, pulmonary edema, thrombocytopenia (platelet count \<100,000/µL), elevated liver enzymes (at twice the upper limit), impaired renal insufficiency (serum creatinine \> 1.1mg/dL)

    Time frame: gestational period

  2. early preterm birth

    between 23+0wks and 33+6weeks

    Time frame: gestational period

  3. Late preterm birth

    delivery between 34+0 to 36+6 weeks

    Time frame: gestational period

  4. Severe Fetal growh restrection

    \<3% and \<5% for a given gestational age

    Time frame: gestational period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kim YM, Seong J, Kim JH, Nam G, Kim GJ, Cha HH, Seong WJ, Sung JH, Choi SJ, Oh SY, Roh CR. Efficacy of combining aspirin with hydroxychloroquine in pregnancies at high risk for pre-eclampsia: a prospective, multicentre, open-label, single-arm clinical trial, investigator-initiated study (HUGS study). BMJ Open. 2024 Dec 10;14(12):e081610. doi: 10.1136/bmjopen-2023-081610. PubMed 39658277 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2022 (actual). Primary completion is estimated for Dec 2027, 67 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2022
First posted
Mar 18, 2022
StartActual
May 31, 2022
Primary completionEst.
Dec 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Dec 31, 2027
Nov 2, 2026
Sponsor
Yoo-min Kim→Samsung Medical Center
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Dec 31, 2026→Dec 31, 2027
    Sponsor Yoo-min Kim→Samsung Medical Center
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05287321
Collaborators
Ministry of Health & Welfare, Korea
Responsible party
Oh Soo Young (professor, Samsung Medical Center) — Principal investigator
First posted
Mar 18, 2022
Start date
May 31, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Yoo-min Kim, MD
Contact
yoominkim@cau.ac.kr
+82-2-6299-1661
Yoo-min Kim, MD
principal investigator · Chung-Ang University Gwangmyeong Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydroxychloroquine

Start the discussion